Healthcare Jul 30, 2021 09:12 AM (GMT+8) · EqualOcean
On the 30th, yiouda health learned that neukio Biotechnology Co., Ltd. (hereinafter referred to as "neukio biotechnology") announced the completion of an angel round of financing of US $40 million, which was led by Eli Lilly Asia Fund, with investors including IDG capital and Sherpa investment. The funds will be mainly used for the construction of R & D facilities and the early development of general spot immune cell technology platform and products. Founded in May 2021, xingyi'ang biology focuses on the R & D and industrialization of immune cell drugs. Through the combination of independent innovation and R & D and the cooperative introduction of global leading companies and institutions, it develops ipsc-car-nk universal spot immune cell products, and is committed to providing effective therapeutic drugs for tumor patients around the world. Wang Liqun, founder, chairman and CEO of xingyi'ang, has rich professional technology and R & D management experience in the field of biopharmaceutical in the United States and China. He was the founding president of Fosun Kate, a joint venture between Fosun Pharmaceutical and American Kate. It took less than three years to complete the technical landing, registration, clinical trial, production facility construction and listing application of yikaida, and finally became the first car-t product approved for listing by China food and drug administration. At present, xingyi'ang is forming a core team.

This text is a result of machine translation.